PERA: Where Patent Law and Healthcare Issues Collide

“Given that the U.S. leads global pharmaceutical and biotechnology investment by far, the ability to protect its investment in innovation with patents is critical not only to the industry, but to the U.S. healthcare system as a whole.”

PERAU.S. Supreme Court opinions in Mayo Collaborative Services v. Prometheus Laboratories, Inc., Association for Molecular Pathology v. Myriad Genetics, Inc., and Alice Corporation Pty. Ltd. V. CLS Bank International et al., produced significant challenges to and unpredictability in obtaining and enforcing patent protection in areas including precision medicine, diagnostics, AI, and pharmaceutical treatments. The Patent Eligibility Restoration Act of 2025 (PERA), S. 1546 and the identical H.R. 3152, seek to address these challenges by rewriting 35 U.S.C. § 101 to eliminate all of these “judicial exceptions to patent eligibility.” The stakes are particularly high in the life sciences, where U.S. courts have invalidated diagnostic and gene claims of the kind protected abroad.

Senators Thom Tillis (R-N.C.) and Chris Coons (D-Del.) introduced a third version of PERA on May 1, 2025. Senate Judiciary hearings followed in October 2025  and July 2026, but no markup has been held, and the 119th Congress ends January 3, 2027, at which time Senator Tillis will retire. It is unclear who the proponents of such a bill will be in the next Congress.  However, given the current administration’s strong support of innovation and patent rights, there is hope that the mission to amend Section 101 will move forward, despite significant opposition from some special interest groups.

Proposed Section 101(b) would exclude unmodified human genes and natural materials, treating a gene as modified if purified, enriched, otherwise altered or used in a useful invention, but not if merely isolated; for other natural materials, isolation would suffice. Proposed Section 101(c)(1) would bar disregarding claim elements as conventional or naturally occurring, the analysis on which Mayo turned.

Analysis

A Record Hostile to Diagnostics

Myriad held that isolating a gene “is not an act of invention.” The Federal Circuit has since struck down diagnostics claim after claim. In Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015), it invalidated claims to detecting cell-free fetal DNA in maternal blood, an invention Judge Linn, concurring only because Mayo bound him, called a breakthrough. Dissenting from the denial of rehearing en banc in Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC, Judge Moore, joined by three colleagues, wrote that the court had “held every single diagnostic claim in every case before us ineligible.” 927 F.3d 1333, 1352 (Fed. Cir. 2019). ChromaDex, Inc. v. Elysium Health, Inc., 59 F.4th 1280 (Fed. Cir. 2023), extended Myriad to compositions of an isolated vitamin. Treatment claims fare somewhat better: Vanda Pharms. Inc. v. West-Ward Pharms. Int’l Ltd., 887 F.3d 1117 (Fed. Cir. 2018), held a genotype-based dosing method eligible.

TRIPS, Europe and China

On the threshold question, U.S. law stands apart. Article 27(1) of the Agreement on Trade-Related Aspects of Intellectual Property Rights requires that patents be “available for any inventions” in all fields of technology that are new, inventive and industrially applicable. Articles 27(2)-(3) permit exclusions for ordre public and morality, medical methods, and plants and animals, but not for laws of nature or abstract ideas. TRIPS does not define “invention” and a World Trade Organization (WTO) panel has tested U.S. eligibility law. BIO’s Hans Sauer told the U.S. Patent and Trademark Office (USPTO) that U.S. judge-made eligibility law is “a significant departure from internationally accepted norms of patentability.”

Europe draws the line differently. Article 53(c) of the European Patent Convention excludes treatment methods and only those diagnostic methods practiced on the body, leaving in vitro diagnostics patentable, and Rule 29(2) allows isolated gene sequences even when identical to natural ones. European Patent Office (EPO) Boards of Appeal upheld BRCA1 probes and an in vitro BRCA predisposition test, T 1213/05 (2007); T 666/05 (2008), while the Federal Circuit held Myriad’s U.S. primer and screening claims ineligible, In re BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig., 774 F.3d 755 (Fed. Cir. 2014). Europe also granted the counterpart of the Ariosa patent.

China is stricter on diagnostic methods but protects more than U.S. law does. Article 25 of China’s Patent Law excludes methods for the diagnosis or treatment of disease, yet CNIPA’s Examination Guidelines allow first-isolated, characterized and industrially useful genes and Swiss-type medical-use claims. Mark Cohen of the Asia Society cited a revised Madigan-Mossoff dataset: 1,310 U.S. applications abandoned after Alice–Mayo rejections had family members granted in China or Europe, 618 of them healthcare-related, led by cancer treatments. (The Patent Eligibility Restoration Act—Restoring Clarity, Certainty, and Predictability to the U.S. Patent System: Hearing Before the Subcomm. on Intellectual Property of the S. Comm. on the Judiciary, 119th Cong. (Oct. 8, 2025)).

What It Means for Patients and Prices

Supporters frame the stakes in patient terms. Cohen in the same hearing testified that eligibility uncertainty discouraged investment in COVID-19 diagnostics, so the United States entered the pandemic with “stronger support for vaccines than for diagnostics.” Former USPTO Director Andrei Iancu, noting that most of the more than 10,000 rare diseases lack an approved treatment, testified that PERA would realign the United States with the rest of the developed world. (From Genes to Machines: The Patent Eligibility Debate: Hearing Before the S. Comm. on the Judiciary, 119th Cong. (July 14, 2026)).

Opponents answer that U.S. pricing, not eligibility, explains the gap. Richard Blaylock of Pillsbury testified that Myriad’s test cost $4,000 because of its patents and that pricing and reimbursement, not eligibility, drive U.S.-European differences. (Questions from Senator Tillis for Richard L. Blaylock, Esq. Pillsbury, Winthrop Shaw Pittman LLP Before the Subcommittee on Intellectual Property of the Committee on the Judiciary United States Senate Hearing on The Patent Eligibility Restoration Act – Restoring Clarity, Certainty, and Predictability to the U.S. Patent System October 8, 2025). Former USPTO Solicitor Thomas Krause submitted that diagnostic patents are less problematic abroad because most countries impose price controls on medical testing. Dr. Debra Leonard of the Association for Molecular Pathology took exception to the assertion that the current patent environment inhibits diagnostic innovation. (Statement of Debra Leonard, M.D., Ph.D. Professor Emerita, Department of Pathology and Laboratory Medicine Robert Larner, M.D. College of Medicine at University of Vermont Before the Committee of the Judiciary United States Senate Hearing on From Genes to Machines: the Patent Eligibility Debate July 14, 2026)).

Drug pricing is of course a major concern of the U.S. public, and purports to be a concern of the current administration. However, given that the U.S. leads global pharmaceutical and biotechnology investment by far, the ability to protect its investment in innovation with patents is critical not only to the industry, but to the U.S. healthcare system as a whole.

Takeaways

  • Diagnostics need jurisdiction-specific claim strategies. An in vitro test that fails under Mayo may be patentable at the EPO but, as a diagnostic method, not in China. Foreign filings should add device, reagent and kit claims and, for China, claims to obtaining intermediate information, which CNIPA’s Guidelines do not treat as diagnosis (pt. II, ch. 1, § 4.3.1.2).
  • Natural-product inventions face the sharpest change. PERA would make isolation enough for natural materials, departing from ChromaDex, but not for human genes. Specifications should document both the human-made alterations PERA would credit and the markedly different characteristics current law requires.
  • Treatment claims remain a U.S. advantage. 35 U.S.C. § 287(c) limits only remedies against medical practitioners, whereas Europe and China exclude treatment methods. One invention can be claimed as a U.S. treatment method, a medical-use product under EPC art. 54(4)-(5) and a Swiss-type use claim in China.

Image Source: Deposit Photos
Author: natatravel
Image ID: 760034748 

Share

Warning & Disclaimer: The pages, articles and comments on IPWatchdog.com do not constitute legal advice, nor do they create any attorney-client relationship. The articles published express the personal opinion and views of the author as of the time of publication and should not be attributed to the author’s employer, clients or the sponsors of IPWatchdog.com.

Join the Discussion

No comments yet. Add my comment.

Add Comment

Your email address will not be published. Required fields are marked *

Varsity Sponsors

From the IPWatchdog Institute

IPWatchdog Events

IPWatchdog LIVE 2027 at the Renaissance Arlington Capital View
April 4, 2027 @ 1:00 pm - April 6, 2027 @ 7:00 pm EDT
Women’s IP Forum 2027
September 8, 2027 @ 8:00 am - September 10, 2027 @ 5:00 pm EDT
Patent Masters™ 2027
October 6, 2027 @ 8:00 am - October 8, 2027 @ 5:00 pm EDT

From IPWatchdog